Do analysts prefer SMTI or DXR?

Sanara MedTech currently has a consensus price target of $34.00, indicating a potential upside of 62.14%. Given Sanara MedTech's higher possible upside, research analysts plainly believe Sanara MedTech is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sanara MedTech 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has preferable earnings and valuation, SMTI or DXR?

Daxor has lower revenue, but higher earnings than Sanara MedTech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanara MedTech $103.12M 1.86 -$37.56M -$3.77 N/A Daxor N/A N/A N/A N/A N/A

Does the media refer more to SMTI or DXR?

In the previous week, Sanara MedTech and Sanara MedTech both had 3 articles in the media. Sanara MedTech's average media sentiment score of 0.63 beat Daxor's score of 0.32 indicating that Sanara MedTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanara MedTech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Daxor 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend LUCD or DXR?

Lucid Diagnostics currently has a consensus target price of $4.13, indicating a potential upside of 310.45%. Given Lucid Diagnostics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Lucid Diagnostics is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lucid Diagnostics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has preferable valuation & earnings, LUCD or DXR?

Daxor has lower revenue, but higher earnings than Lucid Diagnostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lucid Diagnostics $4.71M 43.33 -$58.01M -$0.47 N/A Daxor N/A N/A N/A N/A N/A

Is LUCD or DXR more profitable?

Daxor has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -876.72%. Company Net Margins Return on Equity Return on Assets Lucid Diagnostics -876.72% N/A -116.26% Daxor N/A N/A N/A

Do analysts recommend DXR or PDEX?

Pro-Dex has a consensus price target of $70.00, indicating a potential upside of 7.41%. Given Pro-Dex's higher possible upside, analysts plainly believe Pro-Dex is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Pro-Dex 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has higher earnings and valuation, DXR or PDEX?

Pro-Dex has higher revenue and earnings than Daxor. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Daxor N/A N/A N/A N/A N/A Pro-Dex $66.59M 3.12 $8.98M $3.62 18.00

Is DXR or PDEX more profitable?

Pro-Dex has a net margin of 16.08% compared to Daxor's net margin of 0.00%. Pro-Dex's return on equity of 22.78% beat Daxor's return on equity. Company Net Margins Return on Equity Return on Assets Daxor N/A N/A N/A Pro-Dex 16.08% 22.78% 14.30%

Does the media prefer DXR or PDEX?

In the previous week, Daxor and Daxor both had 3 articles in the media. Pro-Dex's average media sentiment score of 1.15 beat Daxor's score of 0.32 indicating that Pro-Dex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Daxor 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pro-Dex 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend DXR or INFU?

InfuSystem has a consensus target price of $15.00, indicating a potential upside of 66.11%. Given InfuSystem's stronger consensus rating and higher possible upside, analysts clearly believe InfuSystem is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 InfuSystem 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has preferable earnings & valuation, DXR or INFU?

InfuSystem has higher revenue and earnings than Daxor. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Daxor N/A N/A N/A N/A N/A InfuSystem $142.40M 1.28 $870K $0.38 23.76

Is DXR or INFU more profitable?

InfuSystem has a net margin of 1.12% compared to Daxor's net margin of 0.00%. InfuSystem's return on equity of 2.78% beat Daxor's return on equity. Company Net Margins Return on Equity Return on Assets Daxor N/A N/A N/A InfuSystem 1.12% 2.78% 1.41%

Do analysts recommend TLSI or DXR?

TriSalus Life Sciences presently has a consensus price target of $7.50, indicating a potential upside of 135.85%. Given TriSalus Life Sciences' higher probable upside, research analysts plainly believe TriSalus Life Sciences is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TriSalus Life Sciences 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has stronger valuation & earnings, TLSI or DXR?

Daxor has lower revenue, but higher earnings than TriSalus Life Sciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TriSalus Life Sciences $45.15M 4.33 -$39.23M -$1.41 N/A Daxor N/A N/A N/A N/A N/A

Is TLSI or DXR more profitable?

Daxor has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -60.85%. Company Net Margins Return on Equity Return on Assets TriSalus Life Sciences -60.85% N/A -69.91% Daxor N/A N/A N/A

Does the media prefer TLSI or DXR?

In the previous week, TriSalus Life Sciences and TriSalus Life Sciences both had 3 articles in the media. TriSalus Life Sciences' average media sentiment score of 0.70 beat Daxor's score of 0.32 indicating that TriSalus Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TriSalus Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Daxor 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Daxor (DXR) Competitors

$10.70 +0.35 (+3.38%)

As of 04:00 PM Eastern

Compare

DXR vs. SMTI, LUCD, PDEX, INFU, and TLSI

Should you buy Daxor stock or one of its competitors? MarketBeat compares Daxor with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Daxor include Sanara MedTech (SMTI), Lucid Diagnostics (LUCD), Pro-Dex (PDEX), InfuSystem (INFU), and TriSalus Life Sciences (TLSI). These companies are all part of the "medical equipment" industry.

How does Daxor compare to Sanara MedTech?

Sanara MedTech (NASDAQ:SMTI) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

8.1% of Sanara MedTech shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 42.0% of Sanara MedTech shares are held by company insiders. Comparatively, 59.5% of Daxor shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Sanara MedTech has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market. Comparatively, Daxor has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market.

Daxor has a net margin of 0.00% compared to Sanara MedTech's net margin of -31.23%. Daxor's return on equity of 0.00% beat Sanara MedTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-31.23%	-3.19%	-0.56%
Daxor	N/A	N/A	N/A

Daxor has lower revenue, but higher earnings than Sanara MedTech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$103.12M	1.86	-$37.56M	-$3.77	N/A
Daxor	N/A	N/A	N/A	N/A	N/A

Sanara MedTech currently has a consensus price target of $34.00, indicating a potential upside of 62.14%. Given Sanara MedTech's higher possible upside, research analysts plainly believe Sanara MedTech is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Sanara MedTech and Sanara MedTech both had 3 articles in the media. Sanara MedTech's average media sentiment score of 0.63 beat Daxor's score of 0.32 indicating that Sanara MedTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanara MedTech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Daxor	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Sanara MedTech beats Daxor on 6 of the 11 factors compared between the two stocks.

How does Daxor compare to Lucid Diagnostics?

Lucid Diagnostics (NASDAQ:LUCD) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

Daxor has lower revenue, but higher earnings than Lucid Diagnostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$4.71M	43.33	-$58.01M	-$0.47	N/A
Daxor	N/A	N/A	N/A	N/A	N/A

Lucid Diagnostics has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market. Comparatively, Daxor has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market.

Lucid Diagnostics currently has a consensus target price of $4.13, indicating a potential upside of 310.45%. Given Lucid Diagnostics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Lucid Diagnostics is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Daxor has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -876.72%.

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-876.72%	N/A	-116.26%
Daxor	N/A	N/A	N/A

In the previous week, Daxor had 2 more articles in the media than Lucid Diagnostics. MarketBeat recorded 3 mentions for Daxor and 1 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 1.62 beat Daxor's score of 0.32 indicating that Lucid Diagnostics is being referred to more favorably in the media.

Company	Overall Sentiment
Lucid Diagnostics	Very Positive
Daxor	Neutral

74.0% of Lucid Diagnostics shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 6.8% of Lucid Diagnostics shares are held by insiders. Comparatively, 59.5% of Daxor shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Lucid Diagnostics beats Daxor on 7 of the 11 factors compared between the two stocks.

How does Daxor compare to Pro-Dex?

Daxor (NASDAQ:DXR) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

Daxor has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market. Comparatively, Pro-Dex has a beta of -0.02, meaning that its stock price is 102% less volatile than the broader market.

Pro-Dex has a consensus price target of $70.00, indicating a potential upside of 7.41%. Given Pro-Dex's higher possible upside, analysts plainly believe Pro-Dex is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Pro-Dex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Pro-Dex has higher revenue and earnings than Daxor.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daxor	N/A	N/A	N/A	N/A	N/A
Pro-Dex	$66.59M	3.12	$8.98M	$3.62	18.00

Pro-Dex has a net margin of 16.08% compared to Daxor's net margin of 0.00%. Pro-Dex's return on equity of 22.78% beat Daxor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Daxor	N/A	N/A	N/A
Pro-Dex	16.08%	22.78%	14.30%

1.3% of Daxor shares are owned by institutional investors. Comparatively, 15.3% of Pro-Dex shares are owned by institutional investors. 59.5% of Daxor shares are owned by insiders. Comparatively, 45.9% of Pro-Dex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Daxor and Daxor both had 3 articles in the media. Pro-Dex's average media sentiment score of 1.15 beat Daxor's score of 0.32 indicating that Pro-Dex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Daxor	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pro-Dex	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Pro-Dex beats Daxor on 7 of the 10 factors compared between the two stocks.

How does Daxor compare to InfuSystem?

Daxor (NASDAQ:DXR) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

In the previous week, Daxor had 3 more articles in the media than InfuSystem. MarketBeat recorded 3 mentions for Daxor and 0 mentions for InfuSystem. InfuSystem's average media sentiment score of 1.00 beat Daxor's score of 0.32 indicating that InfuSystem is being referred to more favorably in the news media.

Company	Overall Sentiment
Daxor	Neutral
InfuSystem	Positive

Daxor has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market. Comparatively, InfuSystem has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

InfuSystem has a net margin of 1.12% compared to Daxor's net margin of 0.00%. InfuSystem's return on equity of 2.78% beat Daxor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Daxor	N/A	N/A	N/A
InfuSystem	1.12%	2.78%	1.41%

InfuSystem has higher revenue and earnings than Daxor.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daxor	N/A	N/A	N/A	N/A	N/A
InfuSystem	$142.40M	1.28	$870K	$0.38	23.76

1.3% of Daxor shares are owned by institutional investors. Comparatively, 71.1% of InfuSystem shares are owned by institutional investors. 59.5% of Daxor shares are owned by company insiders. Comparatively, 10.8% of InfuSystem shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

InfuSystem has a consensus target price of $15.00, indicating a potential upside of 66.11%. Given InfuSystem's stronger consensus rating and higher possible upside, analysts clearly believe InfuSystem is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

InfuSystem beats Daxor on 10 of the 12 factors compared between the two stocks.

How does Daxor compare to TriSalus Life Sciences?

TriSalus Life Sciences (NASDAQ:TLSI) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

TriSalus Life Sciences has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market. Comparatively, Daxor has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market.

TriSalus Life Sciences presently has a consensus price target of $7.50, indicating a potential upside of 135.85%. Given TriSalus Life Sciences' higher probable upside, research analysts plainly believe TriSalus Life Sciences is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Daxor has lower revenue, but higher earnings than TriSalus Life Sciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$45.15M	4.33	-$39.23M	-$1.41	N/A
Daxor	N/A	N/A	N/A	N/A	N/A

Daxor has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -60.85%.

Company	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-60.85%	N/A	-69.91%
Daxor	N/A	N/A	N/A

2.6% of TriSalus Life Sciences shares are owned by institutional investors. Comparatively, 1.3% of Daxor shares are owned by institutional investors. 16.3% of TriSalus Life Sciences shares are owned by company insiders. Comparatively, 59.5% of Daxor shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, TriSalus Life Sciences and TriSalus Life Sciences both had 3 articles in the media. TriSalus Life Sciences' average media sentiment score of 0.70 beat Daxor's score of 0.32 indicating that TriSalus Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TriSalus Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Daxor	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

TriSalus Life Sciences beats Daxor on 6 of the 10 factors compared between the two stocks.

Get Daxor News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DXR vs. The Competition

Export

Metric	Daxor	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$52.17M	$5.50B	$6.47B	$12.54B
Dividend Yield	N/A	1.59%	2.69%	5.22%
P/E Ratio	N/A	32.83	22.39	24.18
Price / Sales	N/A	25.35	520.79	112.26
Price / Cash	N/A	15.82	41.34	57.13
Price / Book	N/A	3.08	9.84	6.72
Net Income	N/A	$218.81M	$3.57B	$337.19M
7 Day Performance	3.66%	-2.48%	-1.16%	0.48%
1 Month Performance	2.78%	-0.36%	3.85%	5.07%
1 Year Performance	24.33%	10.32%	27.40%	34.25%

Daxor Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DXR Daxor	2.0716 of 5 stars	$10.73 +3.7%	N/A	+23.5%	$52.17M	N/A	N/A	37	News Coverage Gap Up
SMTI Sanara MedTech	1.7598 of 5 stars	$23.64 +2.8%	$34.00 +43.8%	-26.9%	$210.77M	$103.12M	N/A	60
LUCD Lucid Diagnostics	4.0591 of 5 stars	$1.00 flat	$4.13 +312.5%	-17.3%	$203.07M	$5.13M	N/A	70	Positive News
PDEX Pro-Dex	2.5445 of 5 stars	$62.61 -1.4%	$70.00 +11.8%	+70.1%	$202.64M	$66.59M	17.30	140	News Coverage Positive News
INFU InfuSystem	4.1626 of 5 stars	$9.94 -2.2%	$15.00 +50.9%	+57.1%	$200.61M	$142.40M	165.69	410	Positive News High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DXR) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Daxor (DXR) Competitors

DXR vs. SMTI, LUCD, PDEX, INFU, and TLSI

How does Daxor compare to Sanara MedTech?

Summary

How does Daxor compare to Lucid Diagnostics?

Summary

How does Daxor compare to Pro-Dex?

Summary

How does Daxor compare to InfuSystem?

Summary

How does Daxor compare to TriSalus Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DXR vs. The Competition

Daxor Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Daxor (DXR) Competitors

DXR vs. SMTI, LUCD, PDEX, INFU, and TLSI

How does Daxor compare to Sanara MedTech?

Do insiders and institutionals have more ownership in SMTI or DXR?

Which has more risk and volatility, SMTI or DXR?

Is SMTI or DXR more profitable?

Which has preferable earnings and valuation, SMTI or DXR?

Do analysts prefer SMTI or DXR?

Does the media refer more to SMTI or DXR?

Summary

How does Daxor compare to Lucid Diagnostics?

Which has preferable valuation & earnings, LUCD or DXR?

Which has more risk and volatility, LUCD or DXR?

Do analysts recommend LUCD or DXR?

Is LUCD or DXR more profitable?

Does the media favor LUCD or DXR?

Do insiders & institutionals have more ownership in LUCD or DXR?

Summary

How does Daxor compare to Pro-Dex?

Which has more volatility and risk, DXR or PDEX?

Do analysts recommend DXR or PDEX?

Which has higher earnings and valuation, DXR or PDEX?

Is DXR or PDEX more profitable?

Do institutionals and insiders have more ownership in DXR or PDEX?

Does the media prefer DXR or PDEX?

Summary

How does Daxor compare to InfuSystem?

Does the media prefer DXR or INFU?

Which has more risk & volatility, DXR or INFU?

Is DXR or INFU more profitable?

Which has preferable earnings & valuation, DXR or INFU?

Do institutionals & insiders have more ownership in DXR or INFU?

Do analysts recommend DXR or INFU?

Summary

How does Daxor compare to TriSalus Life Sciences?

Which has more risk and volatility, TLSI or DXR?

Do analysts recommend TLSI or DXR?

Which has stronger valuation & earnings, TLSI or DXR?

Is TLSI or DXR more profitable?

Do insiders & institutionals have more ownership in TLSI or DXR?

Does the media prefer TLSI or DXR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DXR vs. The Competition

Daxor Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools